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A comparison of mycophenolate mofetil and calcineurin inhibitor as maintenance
immunosuppression for kidney transplant recipients: A meta-analysis of randomized
controlled trials
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Background/aim: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the comparison
and its timing between mycophenolate mofetil (MMF) and calcineurin inhibitor (CNI) as maintenance immunosuppression for kidney
transplant recipients.
Materials and methods: The RCTs of MMF versus CNI as maintenance immunosuppression for kidney transplant recipients were searched
from PubMed, Embase, Cochrane Central Register of Controlled Trials (CCRCT), and ClinicalTrials.gov. After screening relevant RCTs,
two authors independently assessed the quality of included studies and performed a meta-analysis using RevMan5.3. Relative risk (RR)
was used to report dichotomous data, while mean difference (MD) with 95% confidence interval (CI) was used to report continuous
outcomes. The analysis was conducted using the random-effect model due to the expected heterogeneity among different studies. Four
subgroups were allocated to compare MMF with CNI as maintenance immunosuppression: (1) after 3 months of CNI-based therapy, (2)
after 6 months of CNI-based therapy, (3) after 12 months of CNI-based therapy, and (4) in recipients with allograft dysfunction.
Results: Twelve RCTs with 950 renal transplant recipients were included. This meta-analysis presented the following results upon
comparison between MMF and CNI as maintenance immunosuppression for kidney transplant recipients: (1) MMF significantly
improved the glomerular filtration rate (GFR) not only in the comparison performed after 3, 6, or 12 months of CNI-based therapy
but also in the comparison of recipients with allograft dysfunction, (2) MMF may increase the risk of acute rejection in the comparison
performed after 3 months of CNI-based therapy, but no increase was noted in the comparison performed after 6 or 12 months of CNIbased therapy.
Conclusion: Our present meta-analysis suggested that MMF followed at least 6 months of CNI-based therapy is an effective maintenance
immunosuppressive regimen for kidney transplant recipients to improve renal function but not increase rejection.
Key words: Kidney transplantation, mycophenolate mofetil, calcineurin inhibitor, meta-analysis

1. Introduction
End-stage renal disease (ESRD) is a chronic, irreversible
decline in kidney function that severely and deleteriously
affects the duration and quality of life of patients.
Approximately 1.9 million patients receive renal replacement
therapy (RRT) worldwide [1]. RRT, which includes kidney
transplantation (KT), hemodialysis (HD), and peritoneal
dialysis (PD), is the only option for individuals with ESRD
to survive at present. Compared to dialysis, KT prolongs
the life-span, improves renal function and quality of life,
and is more cost-effective [2–5]. Nevertheless, a suitable
and effective immunosuppressive regimen that minimizes
acute rejection (AR) and limits adverse events (AEs) is
paramount for KT success. Regarding immunosuppressive

therapy, calcineurin inhibitors (CNIs), such as cyclosporine
A (CsA) or tacrolimus (TAC), have served as fundamental
therapies for renal allograft recipients since CsA became
available in the early 1980s. However, significant AEs,
such as hypertension, dyslipidemia, new-onset diabetes
after transplantation (NODAT), and particularly
nephrotoxicity of CNI, have been noted and they serve
as major causes of later graft loss [6]. Mycophenolate
mofetil (MMF), a prodrug of mycophenolic acid (MPA),
which inhibits T and B lymphocyte proliferation, has
been shown to reduce the risk of acute allograft rejection
and lack nephrotoxicity [7,8]. Moreover, a meta-analysis
demonstrated the positive effect of CNI sparing with MMF
as solo adjunctive immunosuppressive agents after KT [9].
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Several randomized controlled trials (RCTs) compared the
outcomes after MMF or CNI withdrawal in renal transplant
recipients [10–12]. However, to date, meta-analysis data
are not available to compare the efficacy and safety of MMF
with CNI as maintenance immunosuppression for kidney
transplant recipients. In addition, given the correlation
between the duration of CNI and its therapeutic efficacy
and side effects, we conducted a systematic review and
meta-analysis of RCTs to evaluate the comparison and
its timing between MMF and CNI as maintenance
immunosuppression for kidney transplant recipients.
2. Materials and methods
2.1. Search strategy
PubMed, Embase, Cochrane Central Register of Controlled
Trials (CCRCT), and ClinicalTrials.gov were searched
without language restrictions using the following mesh
terms and entry terms: kidney transplantation, renal
transplantations, kidney grafting, mycophenolate mofetil,
mycophenolate sodium, cellcept, calcineurin inhibitors,
protein phosphatase-2b inhibitors, calcineurin antagonists,
cyclosporine, cyclosporine a, tacrolimus, and FK506 (all
to September 2019). We retrieved the reference lists of all
relevant trials and consulted experts in the field to identify
potentially relevant studies.
2.2. Inclusion criteria
For inclusion in this meta-analysis, studies had to meet
the following criteria: (1) Only RCTs were considered, (2)
Patients received renal transplant from a living or deceased
donor, (3) Studies compared the outcomes of the use of
MMF to CNI as maintenance immunosuppression for
kidney transplant recipients, (4) Trials analyzed primary
outcomes, including renal function, acute rejection, graft
survival, or patient survival. Studies with complete CNI
avoidance in de novo patients or multiple organ transplant
recipients were excluded. The studies were subsequently
allocated to four subgroups to compare MMF and CNI
as maintenance immunosuppression: (1) after 3 months
of CNI-based therapy, (2) after 6 months of CNI-based
therapy, (3) after 12 months of CNI-based therapy; and (4)
in recipients with allograft dysfunction.
2.3. Study selection
Two authors separately examined the titles and/or
abstracts of each study and excluded irrelevant trials.
Subsequently, the full text of all articles was scanned and
evaluated independently by two authors strictly according
to the inclusion criteria. All disagreements regarding
study eligibility for inclusion were discussed to achieve a
consensus.
2.4. Data extraction
Two authors independently extracted data on the baseline
demographic characteristics of participants, study design,

intervention and control treatment, and outcome data of
studies. We contacted the trial authors or sponsors directly
to obtain the required information if data were unavailable.
When disagreements occurred, the third author provided
an opinion to resolve the issue.
2.5. Study quality assessment
Two authors independently evaluated the quality of
the included studies. Disagreements were resolved by
consensus. The quality of included studies was evaluated by
the Cochrane Handbook [13]. The risk of bias comprised
a description and judgment for the following criteria:
random sequence generation, allocation concealment,
blinding of participants and personnel, blinding of
outcome assessment, incomplete outcome data, selective
reporting, other source of bias. Each criterion was judged
‘low risk of bias’, ‘unclear risk of bias’, or ‘high risk of bias’.
2.6. Statistical analysis
Outcomes were analyzed using Cochrane Review Manager
Software (RevMan5.3, Copenhagen, Denmark: the
Nordic Cochrane Centre, the Cochrane Collaboration).
Continuous variables are expressed as the mean difference
(MD) and 95% confidence interval (CI). The risk ratio
(RR) and 95%CI were calculated for dichotomous data.
If there are no events in one arm or two arms, the data
also will be filled truthfully in the forest figures. The I2statistic and Chi-squared test were used to assess the
heterogeneity of the included studies (I2>50% and p<0.1
indicated significant heterogeneity)[14]. If significant
heterogeneity was present among trials, the random-effect
model was used. Otherwise, the fixed-effect model was
used. Publication bias was evaluated using a funnel plot.
3. Results
3.1. Literature selection
The literature search is presented in Figure 1. A total of 2350
articles were retrieved, and 2324 studies were excluded
after examining the titles and abstracts. After reading the
full text of the remaining 26 trials, we identified 12 eligible
studies for inclusion in the meta-analysis that strictly
fulfilled the inclusion and exclusion criteria. Three trials
investigated comparison after 3 months of CNI-based
therapy [12,15,16], two trials investigated comparison
after6 months of CNI-based therapy [11,17], three trials
investigated comparison after12 months of CNI-based
therapy [10,18,19], and four trials that investigated
comparison in recipients with allograft dysfunction [20–
23].
3.2. Study characteristics and quality assessment
A total of 950 eligible renal transplant recipients were
included in the meta-analysis, of whom 497 were treated
with MMF, and 453 were treated with CNI. All studies
reported randomization. Six studies reported random
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Figure 1. Flow chart of literature selection.

sequence generation and allocation concealment
[11,17,18,20,21,23]; however, no studies referred to
double-blinding. The baseline characteristics of the
included studies are summarized in Table 1, and the risk
of bias are showed in Figure 2.
3.3. Glomerular filtration rate
Nine studies that reported changes of the GFR were
included in the meta-analysis. Compared to CNI, MMF
significantly improved the GFR after CNI-based therapy

1082

(MD 8.47, 95%CI (7.79, 9.14), p < 0.00001) (Figure 3).
Subgroup analysis showed similar effects in comparison
after 3, 6, or 12 months of CNI-based therapy (3 months:
MD 10.11, 95%CI (5.77, 14.46), p < 0.00001; 6 months:
MD 8.40, 95%CI (7.71, 9.09), p < 0.00001 or 12 months:
MD 19.00, 95%CI (5.02, 32.98), p = 0.008) (Figure 3).
Furthermore, MMF also significantly improved the GFR
in comparison of recipients with allograft dysfunction
compared with CNI (MD 7.20, 95%CI (4.09, 10.32), p <
0.00001) (Figure 3).
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Table 1. Baseline characteristics of the included studies.
Subgroup

Study

N

T: 6
Hoerning 2012
C: 8

Comparison
after 3
months of
Hazzan 2005
CNI-based
therapy

Schnulle 2002

Comparison Stevens 2014
after 6
months of
CNI-based
Mourer 2012
therapy

Asberg 2013
Comparison
after 12
months of
Albano 2012
CNI-based
therapy

Mean age (years)*
Recipient
T: 46 ± 9.8
C: 60 ±11.5

donor
—

Sex
(M/F)

Intervention

Duration
(M)

T: 2/4
C: 3/5

MPA +CsA +Bas+ CS for 3 mo, then
T: EVL+ CS+ MPA (0.72g b.i.d); C:
EVL+CS+ Low-CsA (target level:50–
75ng/mL)

12

T: 54 T: 45.1 ± 11.2 T: 40.0 ± 14.0
C: 54 C: 42.5 ± 12.1 C: 36.7 ± 13.1

MMF+ CsA + ATG+ CS for 3 mo, then
T: 32/22
T: CS+ MMF (2g q.d ); C: CS+ CsA
C: 36/18
(target level:100–300ng/mL)

12

T: 44 T: 44.7 ± 13.3 T: 40.7 ± 15.3
C: 40 C: 51.3 ± 11.5 C: 47.7 ± 15.4

MMF+ CsA + CS for 3 mo, then
T: 32/12
T: CS+ MMF (1g b.i.d); C: CS+ CsA
C: 22/18
(target level:100–250ng/mL)

12

T:90
C:88

TAC+ SRL+ATG+ CS for 6 mo, then
T: 62/28
T: SRL+ MMF (1g b.i.d); C: SRL+ TAC
C: 59/29
(target level:2–4ng/mL)

24

T:47.9 ± 12.1
C:46.5 ± 11.6

T: 39.3 ± 13.1
C: 42.6 ± 12.1

T: 79 T: 52.5 ± 10.8 T: 43.3 ± 16.6
C: 79 C: 52.7 ± 13.0 C: 42.5 ± 14.4

MMF+ CsA or TAC + CS for 6 mo, then
T: 56/23 T: CS+ MMF (AUC:75ug.hr/ml); C:
36
C: 54/25 CS+ CsA (AUC3250ng.hr/ml) or TAC
(AUC120ng.hr/mL)

T: 20 T: 63.0 ± 11.2
—
C: 19 C: 56.4 ± 13.4

T: 12/8
C: 14/5

MMF+ CsA+ CS for 12 mo, then
T: CS+ MMF (2g q.d); C: CS+ CsA
(target level:75–125ng/mL)

T:15
C:15

T: 64.7 ± 12.0
C: 62.9 ± 9.8

T: 13/2
C: 11/4

CsA +EVL+ CS for 12 mo, then
T: EVL+ CS+ MMF (0.72g b.i.d); C:
12
EVL+ CS+ CsA (target level:200–450ng/
mL)

—

T: 8/10
C: 14/4

MMF+ CsA+ CS for 12 mo, then
T: CS+ MMF (0.6g b.i.d); C: CS+ CsA
(target level:150–200ng/mL)

24

T:55/15
C:27/4

T: MMF (2g q.d) +half dose of CsA
(target level: not available)
C: CsA standard- dose (target
level:>80ng/mL)

24

T:58.8 ± 7.6
C:62.3 ± 9.5

Cransberg 2007

T: 18 T: 11.9a
C: 18 C: 10.9a

Frimat 2006

T:70 T:43.8 ± 10.6
C: 31 C:44.7 ± 11.1

—

T: 73 T:43(18–63)b
C: 70 C:43(18–63)b

T:CS+ MMF (2g q.d)
T:43.8(13-72)b T: 45/28
C: CsA-based standard therapy (target
b
C:34.8(10-65) C: 44/26
level:>80ng/mL)

Comparison Dudley 2005
in allograft
dysfunction
recipients
Stoves 2004

Mcgrath 2001

T: 13
—
C: 16
T: 15 T: 50.4 ± 8.3
C: 15 C: 42.6 ± 3.1

—

T: 41.8 ± 5.0
C: 40.9 ± 2.7

12

14

—

T: MMF (1g b.i.d) + reduced dose of
CsA (target level:75–100ng/mL)
6
C: CsA standard- dose (target level: unit
standard)

T: 10/5
C: 10/5

T: MMF+ CS (2g q.d)
C: AZA+ CS+ TAC (target level:8–12ng/ 8
mL)

MMF, mycophenolate mofetil; CNIs, calcineurin inhibitors; CsA, cyclosporine A; TAC, tacrolimus; TAC-Elim, TAC-elimination; SRL,
sirolimus; ATG, antithymocyte globulin; Bas, basiliximab; Dac, daclizumab; EVL, everolimus; AZA, azathioprine; MPA, mycophenolate
sodium; CS, corticosteroids; KT: kidney transplantation. *Data are represented as mean ± standard deviation (SD); — means data
deficiency; T, treatment group; C, control group; N, number; a Values were expressed as mean; b Values were mean (range); AUC, area
under the time-blood concentration curve.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all
included studies.

3.4. Graft loss
No significant difference in graft loss (including death) was
observed between the MMF group and the CNI group after
CNI-based therapy (RR 1.01, 95%CI (0.62, 1.67), p = 0.95).
Subgroup analysis showed similar effects in comparison
after 3, 6, or 12 months of CNI-based therapy (3 months:
RR 2.73, 95%CI (0.11, 65.24), p = 0.53; 6 months: RR
0.68, 95%CI (0.32, 1.42), p = 0.30 or 12 months: RR 1.60,
95%CI (0.80, 3.23), p = 0.19). Similar effect was also seen
in comparison of recipients with allograft dysfunction (RR
0.91, 95%CI (0.36, 2.33), p = 0.84). The fixed-effect model
was used for the meta-analysis given that no heterogeneity
was noted among the included studies. One study was
excluded for analysis due to the absence of graft loss data
[15]. The results are presented in Figure 4.
3.5. Mortality
Eleven included studies reported mortality data. There were
no significant differences in mortality between the MMF
and CNI groups after CNI-based therapy (RR 0.71, 95%CI
(0.37, 1.35), p = 0.30). Subgroup analysis showed similar
effects in comparison after 3, 6, or 12 months of CNI-based
therapy (3 months: could not be estimated; 6 months: RR
0.63, 95%CI (0.25, 1.58), p = 0.33 or 12 months: RR 0.82,
95%CI (0.34, 2.01), p = 0.67). Moreover, there was also
no significant difference in mortality between the MMF
and CNI groups in comparison of recipients with allograft
dysfunction (RR 6.72, 95%CI (0.35, 127.71), p = 0.21). The
fixed-effect model was used given the lack of heterogeneity
among the studies. The results are presented in Figure 5.
3.6. Acute rejection
MMF was associated with increased episodes of acute
rejection (biopsy proven) compared with CNI after CNIbased therapy (RR 2.05, 95%CI (1.27, 3.32), p = 0.003).
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Similar effect was seen in comparison after 3 months of
CNI-based therapy (RR 2.90, 95%CI (1.10, 7.64), p =
0.03) when subgroup analysis was performed. However,
no significant differences in acute rejection were found
between the MMF and CNI groups for comparison after
6 or 12 months of CNI-based therapy (6 months: RR
1.59, 95%CI (0.83, 3.02), p = 0.16 or 12 months: RR 2.51,
95%CI (0.81, 7.72), p = 0.11). No acute rejection episodes
occurred in recipients with allograft dysfunction. The
fixed-effect model was used given the lack of heterogeneity
among the studies. The results are presented in Figure 6.
3.7. Adverse events
A comparison of adverse events in the MMF and CNI
groups is shown in Table 2. The random-effect model
was used if significant heterogeneity (I2>50% and p <
0.1) was presented among studies. Otherwise, the fixedeffect model was used instead. The results indicated that
MMF reduced the occurrence rate of proteinuria (RR 0.63,
95%CI (0.43, 0.92), p = 0.02), although the opposite effects
were presented for anemia (RR 2.36, 95%CI (1.46, 3.81),
p = 0.0005) and diarrhea (RR 5.36, 95%CI (2.66, 10.80),
p = 0.00001). The incidence rates of infection, NODAT,
malignancies, and hypertension were similar between the
MMF and CNI groups.
3.8. Publication bias
A funnel plot of acute rejection was examined to evaluate
publication bias. As shown in Figure 7, no publication bias
was observed.
4. Discussion
Kidney transplantation, which is a form of RRT, is an
efficient and preferable option for ESRD patients [3].
However, acute rejection and graft loss represent the
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Figure 3. Forest plot of glomerular filtration rate.

clinical concerns after kidney transplantation (KT). Thus,
safe and effective immunosuppressive therapy is needed
to reduce graft failure caused by acute rejection and CNIrelated nephrotoxicity in the most prevalent CNI-based
immunosuppressive regimes [24, 25]. As a nonnephrotoxic
immunosuppressive drug, MMF improves renal function
without acute rejection after CNI withdrawal [26–28].
Moreover, two studies reported that MMF could have
nephroprotective properties [29,30]. Recently, a metaanalysis suggested that CNI sparing strategies with
adjunctive MMF after KT can improve renal function,
possibly reduce graft loss, and increase rejection rates
only after elective CNI elimination [9]. Thus, MMF may
enhance renal function but not increase rejection and

nephrotoxicity, consequently improving patient and graft
survival.
This is the first meta-analysis to evaluate the comparison
and its timing between MMF and CNI as maintenance
immunosuppression for kidney transplant recipients. We
analyzed the data of 12 studies that compared the use of
MMF and CNI as maintenance immunosuppression for
kidney transplant recipients. The results of our present
meta-analysis indicate that MMF significantly improved
the GFR not only in the comparison performed after 3,
6, or 12 months of CNI-based therapy but also in the
comparison of recipients with allograft dysfunction.
This result suggested the ongoing benefits of using MMF
instead of CNI not only in patients with deteriorating renal
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Figure 4. Forest plot of graft loss (including death).

function but also in patients with stable renal function after
KT regardless of the timing of the alternative. Interestingly,
our present meta-analysis also found that MMF may
increase the risk of acute rejection in the comparison
performed after 3 months of CNI-based therapy, but no
increase was noted in the comparison performed after 6
or 12 months of CNI-based therapy. Taken together, the
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results of this analysis indicate that MMF offers similar
efficiency as CNI after at least 6 months of CNI-based
therapy as maintenance immunosuppression for kidney
transplant recipients, while MMF appears safer than CNI,
as reflected by its protective effects on renal function.
However, this finding must be further demonstrated by
more large-scale, high-quality, and long-term studies. In

HONG et al. / Turk J Med Sci

Figure 5. Forest plot of mortality.

addition, MMF is associated with a reduced incidence of
proteinuria, whereas the opposite effects were noted for
anemia and diarrhea compared to CNI.
Several limitations to this meta-analysis should be
noted. Above all, most of the included trials had small
samples and were not multicenter RCTs. In addition, no
studies were double-blinded. Furthermore, data from
some studies were unavailable or deficient and could not be
obtained from the original authors, which may weaken the

evidence of the results. Moreover, given that a few studies
in each subgroup and several studies with a short duration,
the efficacy and safety of MMF for renal transplant
recipients must be proven by further large-scale and
long-term studies. Finally, some heterogeneity in clinical
features, such as the immunosuppressive therapy and drug
dosages, was noted; however, the included studies had
similar baseline characteristics. Thus, more large-scale,
high-quality, and multicenter RCTs with longer duration
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Figure 6. Forest plot of acute rejection (biopsy proven).

times and reduced heterogeneity are required to address
the above limitations.
In conclusion, the result of our present meta-analysis is that
MMF offers similar efficiency as CNI after at least 6 months of
CNI-based therapy as maintenance immunosuppression for
kidney transplant recipients, while MMF appears safer than
CNI, as reflected by its protective effects on renal function. It is
suggested that MMF followed at least 6 months of CNI-based
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therapy is an effective maintenance immunosuppressive
regimen for kidney transplant recipients to improve renal
function but not increase rejection. However, these results
must be confirmed in future studies.
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Table 2. Summary of adverse events of included studies comparing MMF with CNI groups as maintenance immunosuppression after
kidney transplantation.
Outcome

Studies MMF group CNI group

Heterogeneity
(P, I2)

Infection

7

156/384

117/339

0.006, 66%

Anemia

5

56/250

20/211

0.61, 0%

Diarrhea

5

54/281

8/235

0.32, 15%

NODAT

5

25/241

28/238

0.77, 0%

Malignancies

4

12/254

13/198

0.77, 0%

Proteinuria

3

34/139

30/100

0.38, 0%

5/88

11/85

0.35, 0%

Hypertension 2

Statistical method
Risk ratio
(M-H, Random, 95%CI)
Risk ratio
(M-H, Fixed, 95%CI)
Risk ratio
(M-H, Fixed, 95%CI)
Risk ratio
(M-H, Fixed, 95%CI)
Risk ratio
(M-H, Fixed, 95%CI)
Risk ratio
(M-H, Fixed, 95%CI)
Risk Ratio
(M-H, Fixed, 95%CI)

Effect estimate

P value

1.19(0.83, 1.73)

0.34

2.36 (1.46, 3.81)

0.0005

5.36 (2.66, 10.80) 0.00001
0.86 (0.53, 1.42)

0.56

0.84 (0.39, 1.84)

0.66

0.63 (0.43, 0.92)

0.02

0.46 (0.17, 1.23)

0.12

MMF, mycophenolate mofetil; CNI, calcineurin inhibitor; NODAT, new-onset diabetes mellitus after transplantation.

Figure 7. Funnel plot for acute rejection.
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